Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Free Cash Flow (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Free Cash Flow for 13 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 206.53% to -$4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.0 million, a 21.31% decrease, with the full-year FY2025 number at -$12.0 million, down 21.31% from a year prior.
  • Free Cash Flow was -$4.5 million for Q4 2025 at Ekso Bionics Holdings, down from -$2.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q4 2024 to a low of -$4.5 million in Q4 2025.
  • A 5-year average of -$3.0 million and a median of -$3.0 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 55.99% in 2023, then tumbled 206.53% in 2025.
  • Ekso Bionics Holdings' Free Cash Flow stood at -$3.1 million in 2021, then decreased by 20.27% to -$3.7 million in 2022, then surged by 55.99% to -$1.6 million in 2023, then rose by 10.63% to -$1.5 million in 2024, then crashed by 206.53% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Free Cash Flow are -$4.5 million (Q4 2025), -$2.1 million (Q3 2025), and -$3.5 million (Q2 2025).